DK0637959T3 - Opløselige probucolanaloger - Google Patents

Opløselige probucolanaloger

Info

Publication number
DK0637959T3
DK0637959T3 DK93910932T DK93910932T DK0637959T3 DK 0637959 T3 DK0637959 T3 DK 0637959T3 DK 93910932 T DK93910932 T DK 93910932T DK 93910932 T DK93910932 T DK 93910932T DK 0637959 T3 DK0637959 T3 DK 0637959T3
Authority
DK
Denmark
Prior art keywords
chamber
tray
test strip
reaction vessel
fluid conduit
Prior art date
Application number
DK93910932T
Other languages
Danish (da)
English (en)
Inventor
Sampath Parthasarathy
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Application granted granted Critical
Publication of DK0637959T3 publication Critical patent/DK0637959T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93910932T 1992-04-30 1993-04-30 Opløselige probucolanaloger DK0637959T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/876,557 US5262439A (en) 1992-04-30 1992-04-30 Soluble analogs of probucol
PCT/US1993/004071 WO1993021914A1 (fr) 1992-04-30 1993-04-30 Analogues solubles de probucol

Publications (1)

Publication Number Publication Date
DK0637959T3 true DK0637959T3 (da) 2002-12-23

Family

ID=25368007

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93910932T DK0637959T3 (da) 1992-04-30 1993-04-30 Opløselige probucolanaloger

Country Status (12)

Country Link
US (1) US5262439A (fr)
EP (2) EP0637959B1 (fr)
JP (1) JP3179494B2 (fr)
AT (1) ATE222490T1 (fr)
AU (1) AU4225493A (fr)
CA (1) CA2134679C (fr)
CY (1) CY2426B1 (fr)
DE (1) DE69332220T2 (fr)
DK (1) DK0637959T3 (fr)
ES (1) ES2181688T3 (fr)
PT (1) PT637959E (fr)
WO (1) WO1993021914A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
AU2002300328B2 (en) * 1997-05-14 2006-04-13 Atherogenics, Inc Compounds and methods for the inhibition of the expression of VCAM-1
AU2006202461B2 (en) * 1997-05-14 2009-12-03 Atherogenics, Inc. Compositions and methods for the inhibition of the expression of VCAM-1
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
EP1468989A3 (fr) * 1997-05-14 2008-12-03 Atherogenics, Inc. Composés et méthodes d'inhibition de l'expression de VCAM-1
BR9809793A (pt) 1997-05-14 2000-06-27 Atherogenics Inc Monoésteres de probucol para o tratamento de doença inflamatória e cardiovascular
EP1607089A1 (fr) * 1997-05-14 2005-12-21 Atherogenics, Inc. Monoster de probucol destinés au traitement de troubles cardio-vasculaires et inflammatoires
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
EP1695959A1 (fr) * 1997-05-14 2006-08-30 Atherogenics, Inc. Composes et methodes d'inhibition de l'expression de VCAM-1
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
KR20010020611A (ko) * 1997-07-01 2001-03-15 아테로제닉스, 인코포레이티드 항산화제에 의한 과증식질병 치료의 향상
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6887712B1 (en) * 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
CA2404044A1 (fr) 2000-04-11 2001-10-18 Atherogenics, Inc. Composes et procedes destines a accroitre les niveaux plasmatiques de hdl cholesterol et a ameliorer la fonctionnalite de hdl
US6323359B1 (en) * 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
AUPQ872800A0 (en) * 2000-07-12 2000-08-03 Heart Research Institute, The Compositions and methods for treating cardiovascular disorders
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030064967A1 (en) * 2001-04-11 2003-04-03 Jayraz Luchoomun Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
US6651862B2 (en) 2001-04-30 2003-11-25 Illinois Tool Works Inc. Trim-type fastener driving tool
KR20050039700A (ko) * 2001-10-25 2005-04-29 아테로제닉스, 인코포레이티드 이식거부 치료용 화합물 및 치료 방법
IL161741A0 (en) * 2001-11-09 2005-11-20 Atherogenics Inc Methods of reversing and preventingcardiovascular pathologies
ITMI20020597A1 (it) * 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
CA2492433A1 (fr) * 2002-07-12 2004-01-22 Artherogenics, Inc. Sels d'amines organiques d'esters et d'ethers de probucol faiblement solubles
US20040110803A1 (en) * 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
BRPI0406738A (pt) 2003-01-13 2005-12-20 Atherogenics Inc Processo de preparação de ésteres e éteres de probucol e derivados desse
CH696357A5 (de) * 2003-02-14 2007-05-15 Siegfried Ltd Verfahren zur Herstellung von Probucolverbindungen.
GB0321613D0 (en) * 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
US20060025481A1 (en) * 2004-02-09 2006-02-02 Strange Matthew L Process for preparation of probucol derivatives and polymorphic forms thereof
US7294736B2 (en) * 2004-04-09 2007-11-13 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
US7294737B2 (en) * 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
WO2005112914A2 (fr) 2004-04-20 2005-12-01 Atherogenics, Inc. Antioxydants phénoliques pour le traitement de troubles incluant l’arthrite, l’asthme et les troubles des artères coronaires
WO2006007508A2 (fr) * 2004-07-01 2006-01-19 Atherogenics, Inc. Composes et methodes de traitement des maladies vasculaires diabetiques
EP1844009A4 (fr) * 2004-12-17 2010-04-21 Roland O Stocker Préparations et méthodes pour le traitement de troubles cardio-vasculaires
US20060194981A1 (en) * 2005-02-26 2006-08-31 Jass Paul A Process for preparation of probucol derivatives
US7345191B2 (en) * 2005-02-26 2008-03-18 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
EA200702292A1 (ru) * 2005-04-21 2008-04-28 Атеродженикс, Инк. Способ разделения производных пробукола
EP1776970A1 (fr) 2005-10-12 2007-04-25 Albert Schömig Implant avec revêtement multiple
EP1916006A1 (fr) * 2006-10-19 2008-04-30 Albert Schömig Implant revêtu de cire ou de résine
EP1913960A1 (fr) 2006-10-19 2008-04-23 Albert Schömig implant enrobé
US8252840B2 (en) * 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes
US20080280985A1 (en) * 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
US7897776B2 (en) 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
JP2010531354A (ja) * 2007-06-26 2010-09-24 アストラゼネカ アクチボラグ カルボキシ基で一置換されたプロブコール誘導体の単離方法
WO2016020315A1 (fr) * 2014-08-04 2016-02-11 Università degli Studi di Parma Nouveaux inhibiteurs mdr1 pour surmonter la résistance multiple aux médicaments
CN106905208B (zh) * 2017-02-27 2018-09-07 江西瑞雅药业有限公司 普罗布考前药及其制备方法和药物组合物
CN108299263B (zh) 2018-01-30 2020-12-01 北京德默高科医药技术有限公司 一种普罗布考衍生物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862332A (en) * 1967-05-11 1975-01-21 Dow Chemical Co Method of lowering serum cholesterol
US3485843A (en) * 1967-05-11 1969-12-23 Dow Chemical Co Piperazine adducts of ketone mercaptoles
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
FR2130975A5 (en) * 1971-03-29 1972-11-10 Aries Robert Bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes - hypolipemics hypocholesterolemics
FR2133024A5 (en) * 1971-04-06 1972-11-24 Aries Robert Bis-(4-nicotinoyloxyphenylthio) propanes - with hypocholesterolaemic and hypolipaemic activity
FR2168137A1 (en) * 1972-01-17 1973-08-31 Dynachim Sarl Bis 4-hydroxyphenylthioalkane esters - with hypocholesterolaemic and hypolipaemic activities
DE3442639A1 (de) * 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
US4719237A (en) * 1986-01-28 1988-01-12 Merrell Dow Pharmaceuticals Inc. Cardiac antiarrythmic method employing probucol
US4985465A (en) * 1989-07-14 1991-01-15 Hendler Sheldon S Method for inhibiting viral and retroviral infections

Also Published As

Publication number Publication date
JPH07506373A (ja) 1995-07-13
CA2134679A1 (fr) 1993-11-11
AU4225493A (en) 1993-11-29
DE69332220T2 (de) 2003-05-08
US5262439A (en) 1993-11-16
JP3179494B2 (ja) 2001-06-25
ES2181688T3 (es) 2003-03-01
DE69332220D1 (de) 2002-09-26
CY2426B1 (en) 2004-11-12
EP0637959B1 (fr) 2002-08-21
EP1161946A3 (fr) 2003-12-10
PT637959E (pt) 2002-12-31
CA2134679C (fr) 2003-11-25
WO1993021914A1 (fr) 1993-11-11
EP0637959A4 (fr) 1995-03-29
EP1161946A2 (fr) 2001-12-12
EP0637959A1 (fr) 1995-02-15
ATE222490T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
DK0637959T3 (da) Opløselige probucolanaloger
DE3260918D1 (en) Improved system for the determination of glucose in fluids
BR9801509A (pt) Vaso de reação, tira de teste, processos para conduzir uma reação de amplificação de ácido nucleico e para transferir um lìquido para dentro de umvaso de reação e estação de amoplificação de ácido nucleico para uma tira de teste.
IL142018A0 (en) Nucleic acid amplification reaction station for disposable test devices
AU3595695A (en) Highly stable oxidative coupling dye for spectrophotometric determination of analytes
FR2391185A1 (fr) Procede de preparation d'ether-carboxylates
IT7919741A0 (it) Dispositivo per la diffusione di sostanze fra due fluidi con temperatura simultanea di almeno uno dei detti fluidi.
DE3279474D1 (en) A method for the preparation of poly(arylene sulfide)
GB2020424A (en) Determination of glucose
NO142590C (no) Kontaktlegeme for vaeske og gass, saerlig for luftfuktere og kjoeletaarn.
GB1509693A (en) Immersion sampler for molten metal
EP0251195A3 (en) Method and reagent for the determination of alpha-amylase
EP0400965A3 (fr) Réacteur d'analyses chimiques
GB8423636D0 (en) Analytical solutions
ZA906998B (en) Process and reagent for the specific determination of pancreatic alpha-amylase
AU8206087A (en) Chromogenic acridinone enzyme substrates
AU546025B2 (en) Agent for detecting ketone-bodies
WO2016017832A1 (fr) Dispositif d'amplification de l'acide nucleique
NO168444C (no) Fremgangsmaate for fremstilling av en stabil, naturlig matriks til anvendelse ved immunologisk paavisning av psa
GR74999B (fr)
SU1450589A1 (ru) Устройство для дифференциально-термического анализа
GR75915B (fr)
DK416285A (da) Fremgangsmaade til fremstilling af 0-alkyl-s-(alfa-forgrenet alkyl)alkylphosphono-thioater
NZ507821A (en) Indirectly determining temperature of blood in a container by measuring temperature of surrounding air and outside surface of container
JPS54157640A (en) Temperature controlelr for microscope specimen chamber